替罗非班治疗不稳定型心绞痛和非ST段抬高心肌梗死49例

Effect of Tirofiban on Unstable Angina and Non ST Elevation Myocardial Infarction in 49 Cases

目的观察替罗非班治疗不稳定型心绞痛和非ST段抬高心肌梗死的安全性和有效性。方法将98例患者随机均分为两组,对照组(49例)予常规治疗,治疗组(49例)加用替罗非班[负荷量0.4μg/(kg.min)30min,维持量0.1μg/(kg.min)48h],比较两组48h和30d内的主要心脏不良事件(MACE)及出血发生率。结果治疗组48h及30d的MACE发生率显著低于对照组(48h:2.04%对16.33%;30d:6.12%对30.61%。P<0.01);出血并发症两组之间无明显差异(P>0.05)。结论替罗非班治疗不稳定型心绞痛和非ST段抬高心肌梗死安全、有效。

Objective To observe the safety and efficacy of tirofiban on unstable angina（UA） and non ST elevation myocardial infarction （NSTEMI）. Methods 98 patients with UA and NSTEMI were randomly divided into the tirofiban group received tirofiban for 48 h and conventional therapy and the control group received conventional therapy. The major adverse cardiac events（MACE） rates within 48 h, 30 d, the incidence of bleeding and transfusion rates were analyzed and compared between two groups. Results The MACE rates within 48 h （2. 04% vs 16. 33% ） and 30 d （6. 12% vs 30. 61% ） in tirofiban group were significantly lower than those in the control group. But there was no difference in the incidence of bleeding between two groups（ P 〉 0. 05）. Conclusion Tirofiban is safe and effective in treating UA and NSTEMI.